These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24122060)

  • 1. Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.
    Herbert MK; Kuiperij H; Bloem BR; Verbeek MM
    J Neurol; 2013 Dec; 260(12):3129-33. PubMed ID: 24122060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
    González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
    Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
    Gibson CJ; Logue M; Growdon JH
    Arch Neurol; 1985 May; 42(5):489-92. PubMed ID: 2581531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.
    Davidson DL; Yates CM; Mawdsley C; Pullar IA; Wilson H
    J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1136-41. PubMed ID: 591981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The changes of monoamine metabolites in CSF of patients with cerebral stroke].
    Tang HZ
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Jun; 24(3):130-2, 186. PubMed ID: 1716195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
    van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP
    J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: A meta-analysis of historic evidence.
    Ogawa S; Tsuchimine S; Kunugi H
    J Psychiatr Res; 2018 Oct; 105():137-146. PubMed ID: 30219563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased concentrations of the monoamine metabolites homovanillic acid and 5-hydroxyindoleacetic acid in lumbar and central CSF and of 3-methoxy-4-hydroxyphenylglycol in lumbar CSF after subarachnoid haemorrhage.
    von Holst H; Lindquist C; Sedvall G
    Acta Neurochir (Wien); 1985; 77(3-4):146-51. PubMed ID: 2416192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine metabolites in the CSF of epileptic patients.
    Laxer KD; Sourkes TL; Fang TY; Young SN; Gauthier SG; Missala K
    Neurology; 1979 Aug; 29(8):1157-61. PubMed ID: 37460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease.
    Abdo WF; De Jong D; Hendriks JC; Horstink MW; Kremer BP; Bloem BR; Verbeek MM
    Mov Disord; 2004 May; 19(5):571-9. PubMed ID: 15133823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
    Nishi K; Kondo T; Narabayashi H; Takubo H; Muramoto S; Araki H
    J Neurol Sci; 1989 Aug; 92(1):65-70. PubMed ID: 2475587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls.
    Engström G; Alling C; Blennow K; Regnéll G; Träskman-Bendz L
    Eur Neuropsychopharmacol; 1999 Sep; 9(5):399-405. PubMed ID: 10523046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease.
    Ueda M; Hamamoto M; Nagayama H; Otsubo K; Nito C; Miyazaki T; Terashi A; Katayama Y
    Neurology; 1999 Mar; 52(4):777-81. PubMed ID: 10078727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics of monoamine metabolites in baboons: overlapping sets of genes influence levels of 5-hydroxyindolacetic acid, 3-hydroxy-4-methoxyphenylglycol, and homovanillic acid.
    Rogers J; Martin LJ; Comuzzie AG; Mann JJ; Manuck SB; Leland M; Kaplan JR
    Biol Psychiatry; 2004 Apr; 55(7):739-44. PubMed ID: 15039003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal reflexes and the concentrations of 5-HIAA, MHPG, and HVA in lumbar cereborspinal fluid after spinal lesions in man.
    Ashby P; Verrier M; Warsh JJ; Price KS
    J Neurol Neurosurg Psychiatry; 1976 Dec; 39(12):1191-200. PubMed ID: 1011029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease.
    Blennow K; Wallin A; Gottfries CG; Lekman A; Karlsson I; Skoog I; Svennerholm L
    Neurobiol Aging; 1992; 13(1):107-13. PubMed ID: 1371850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amine metabolites in ventricular cerebrospinal fluid in coma.
    Yates CM; Tsementzis SA; Wilson H
    J Neurol Neurosurg Psychiatry; 1979 Oct; 42(10):887-91. PubMed ID: 512664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF monoamine metabolites in schizophrenic patients.
    Gattaz WF; Waldmeier P; Beckmann H
    Acta Psychiatr Scand; 1982 Nov; 66(5):350-60. PubMed ID: 6184954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.